TipRanks
Ultragenyx Pharmaceutical (CH:UP0)
:UP0
Switzerland Market
UP0
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports

Ultragenyx Pharmaceutical (UP0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

UP0 Analyst Ratings

Moderate Buy
20Ratings
Moderate Buy
10 Buy
10 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UP0 Stock 12 Month Forecast

Average Price Target

―
Based on 20 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is CHF23.64 with a high forecast of CHF56.45 and a low forecast of CHF13.28. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"CHF9","21":"CHF21","33":"CHF33","45":"CHF45","57":"CHF57"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.45355444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF56.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.638833554210528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF23.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.28318928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF13.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,21,33,45,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.764,14.27858111076923,17.79316222153846,21.30774333230769,24.822324443076923,28.33690555384615,31.851486664615383,35.36606777538461,38.88064888615384,42.39522999692308,45.909811107692306,49.424392218461534,52.93897332923076,{"y":56.45355444,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.764,11.754371811862347,12.744743623724696,13.735115435587044,14.725487247449394,15.715859059311741,16.70623087117409,17.69660268303644,18.686974494898784,19.677346306761134,20.667718118623483,21.65808993048583,22.64846174234818,{"y":23.638833554210528,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.764,10.95778379076923,11.151567581538462,11.345351372307691,11.539135163076923,11.732918953846154,11.926702744615385,12.120486535384615,12.314270326153846,12.508054116923077,12.701837907692308,12.89562169846154,13.089405489230769,{"y":13.28318928,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.898,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.898,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.764,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF56.45Average Price TargetCHF23.64Lowest Price TargetCHF13.28
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF16.6
Hold
―
Reiterated
10/09/26
Analysts Conflicted on These Healthcare Names: Quantum-Si (NASDAQ: QSI), Crispr Therapeutics AG (NASDAQ: CRSP) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
H.C. Wainwright Analyst forecast on CH:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF20.75
Buy
―
Reiterated
10/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (NASDAQ: VSTM), Ultragenyx Pharmaceutical (NASDAQ: RARE) and UnitedHealth (NYSE: UNH)
RBC Capital Analyst forecast on CH:UP0
Luca Issi
RBC Capital
RBC Capital
CHF15.77
Hold
―
Reiterated
10/08/26
Ultragenyx Pharmaceutical (RARE) Receives a Hold from RBC Capital
Evercore ISI Analyst forecast on CH:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF13.28→CHF14.94
Hold
―
Reiterated
09/21/26
Ultragenyx price target raised to $18 from $16 at Evercore ISIUltragenyx price target raised to $18 from $16 at Evercore ISI
Morgan Stanley Analyst forecast on CH:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF14.94→CHF16.6
Hold
―
Assigned
09/21/26
Morgan Stanley Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
Leerink Partners Analyst forecast on CH:UP0
Joseph Schwartz
Leerink Partners
Leerink Partners
CHF27.4
Buy
―
Reiterated
09/18/26
Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Wedbush Analyst forecast on CH:UP0
Laura Chico
Wedbush
Wedbush
CHF19.09
Hold
―
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Heart Test Laboratories, Inc. (NASDAQ: HSCS), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Abeona Therapeutics (NASDAQ: ABEO)
Canaccord Genuity Analyst forecast on CH:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF30.72→CHF32.38
Buy
―
Reiterated
09/18/26
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity
William Blair Analyst forecast on CH:UP0
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
09/18/26
Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts
Citi Analyst forecast on CH:UP0
Yigal Nochomovitz
Citi
Citi
CHF25.74→CHF26.57
Buy
―
Reiterated
09/18/26
Ultragenyx price target raised to $32 from $31 at CitiUltragenyx price target raised to $32 from $31 at Citi
Barclays Analyst forecast on CH:UP0
Eliana Merle
Barclays
Barclays
CHF26.57→CHF29.06
Buy
―
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Novavax (NASDAQ: NVAX)
Wells Fargo Analyst forecast on CH:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF14.94
Hold
―
Assigned
09/18/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Globus Medical (NYSE: GMED)
Cantor Fitzgerald Analyst forecast on CH:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF27.4→CHF32.38
Buy
―
Reiterated
09/17/26
Ultragenyx price target raised to $39 from $33 at Cantor FitzgeraldUltragenyx price target raised to $39 from $33 at Cantor Fitzgerald
Goldman Sachs Analyst forecast on CH:UP0
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF23.25→CHF15.77
Hold
―
Reiterated
09/04/26
Goldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)
TD Cowen Analyst forecast on CH:UP0
Yaron Werber
TD Cowen
TD Cowen
CHF40.68→CHF14.94
Buy
―
Assigned
09/03/26
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Edwards Lifesciences (NYSE: EW)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF16.6
Hold
―
Reiterated
10/09/26
Analysts Conflicted on These Healthcare Names: Quantum-Si (NASDAQ: QSI), Crispr Therapeutics AG (NASDAQ: CRSP) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
H.C. Wainwright Analyst forecast on CH:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF20.75
Buy
―
Reiterated
10/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (NASDAQ: VSTM), Ultragenyx Pharmaceutical (NASDAQ: RARE) and UnitedHealth (NYSE: UNH)
RBC Capital Analyst forecast on CH:UP0
Luca Issi
RBC Capital
RBC Capital
CHF15.77
Hold
―
Reiterated
10/08/26
Ultragenyx Pharmaceutical (RARE) Receives a Hold from RBC Capital
Evercore ISI Analyst forecast on CH:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF13.28→CHF14.94
Hold
―
Reiterated
09/21/26
Ultragenyx price target raised to $18 from $16 at Evercore ISIUltragenyx price target raised to $18 from $16 at Evercore ISI
Morgan Stanley Analyst forecast on CH:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF14.94→CHF16.6
Hold
―
Assigned
09/21/26
Morgan Stanley Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
Leerink Partners Analyst forecast on CH:UP0
Joseph Schwartz
Leerink Partners
Leerink Partners
CHF27.4
Buy
―
Reiterated
09/18/26
Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Wedbush Analyst forecast on CH:UP0
Laura Chico
Wedbush
Wedbush
CHF19.09
Hold
―
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Heart Test Laboratories, Inc. (NASDAQ: HSCS), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Abeona Therapeutics (NASDAQ: ABEO)
Canaccord Genuity Analyst forecast on CH:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF30.72→CHF32.38
Buy
―
Reiterated
09/18/26
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity
William Blair Analyst forecast on CH:UP0
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
09/18/26
Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts
Citi Analyst forecast on CH:UP0
Yigal Nochomovitz
Citi
Citi
CHF25.74→CHF26.57
Buy
―
Reiterated
09/18/26
Ultragenyx price target raised to $32 from $31 at CitiUltragenyx price target raised to $32 from $31 at Citi
Barclays Analyst forecast on CH:UP0
Eliana Merle
Barclays
Barclays
CHF26.57→CHF29.06
Buy
―
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Novavax (NASDAQ: NVAX)
Wells Fargo Analyst forecast on CH:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF14.94
Hold
―
Assigned
09/18/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Globus Medical (NYSE: GMED)
Cantor Fitzgerald Analyst forecast on CH:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF27.4→CHF32.38
Buy
―
Reiterated
09/17/26
Ultragenyx price target raised to $39 from $33 at Cantor FitzgeraldUltragenyx price target raised to $39 from $33 at Cantor Fitzgerald
Goldman Sachs Analyst forecast on CH:UP0
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF23.25→CHF15.77
Hold
―
Reiterated
09/04/26
Goldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)
TD Cowen Analyst forecast on CH:UP0
Yaron Werber
TD Cowen
TD Cowen
CHF40.68→CHF14.94
Buy
―
Assigned
09/03/26
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Edwards Lifesciences (NYSE: EW)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months
Joon LeeTruist Financial
Success Rate
13/23 ratings generated profit
57%
Average Return
+1.75%
Copying Joon Lee's trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +1.75% per trade.
1 Year
Yigal NochomovitzCiti
Success Rate
7/20 ratings generated profit
35%
Average Return
-9.68%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -9.68% per trade.
2 Years
Yigal NochomovitzCiti
Success Rate
4/20 ratings generated profit
20%
Average Return
-25.86%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -25.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UP0 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
16
14
24
36
35
Buy
3
4
7
8
6
Hold
1
4
6
22
21
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
22
37
66
62
In the current month, UP0 has received 41 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. UP0 average Analyst price target in the past 3 months is 23.64.
Each month's total comprises the sum of three months' worth of ratings.

UP0 Financial Forecast

UP0 Earnings Forecast

Next quarter’s earnings estimate for UP0 is -CHF0.77 with a range of -CHF1.07 to CHF0.62. The previous quarter’s EPS was -CHF0.75. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for UP0 is -CHF0.77 with a range of -CHF1.07 to CHF0.62. The previous quarter’s EPS was -CHF0.75. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Sales Forecast

Next quarter’s sales forecast for UP0 is CHF151.49M with a range of CHF133.56M to CHF164.41M. The previous quarter’s sales results were CHF177.52M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s sales forecast for UP0 is CHF151.49M with a range of CHF133.56M to CHF164.41M. The previous quarter’s sales results were CHF177.52M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Stock Forecast FAQ

What is CH:UP0’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 23.64.
    What is CH:UP0’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:UP0, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Ultragenyx Pharmaceutical a Buy, Sell or Hold?
        Ultragenyx Pharmaceutical has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 10 hold ratings and 0 sell ratings.
          What is Ultragenyx Pharmaceutical’s share price target?
          The average share price target for Ultragenyx Pharmaceutical is 23.64. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF56.45 ,and the lowest forecast is CHF13.28. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Ultragenyx Pharmaceutical?
            Ultragenyx Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
              How can I buy shares of Ultragenyx Pharmaceutical?
              To buy shares of CH:UP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.